Med-X Secures Coveted OMRI Listing for Nature-Cide All-Purpose Commercial Concentrate to Allow for Use in Certified Organic Food Processing Facilities

1 year ago

Leading Organic Trade Organization Lists Nature-Cide All-Purpose Commercial Concentrate as Allowed for the Use in Accordance with the National Organic…

Aptevo Therapeutics Reports 3Q 2024 Financial Results and Provides a Business Update

1 year ago

Company Achieves Milestones in Both Clinical ProgramsInitiates Mipletamig Phase 1b/2 Clinical Trial, "RAINIER," in Frontline Acute Myeloid Leukemia, Informed by…

CBD Life Sciences, Inc. (CBDL) Positioned for Unmatched Growth as Trump Welcomes Weed Legalization and Federal Rescheduling

1 year ago

The global cannabis market size was valued at USD 43.72 billion in 2022 and is projected to grow from USD…

Modular Medical Announces Results from a Successful GLP-1 Proof of Concept Study

1 year ago

-Study showed more potent weight loss and blood glucose control with the addition of a mealtime bolus of a rapid…

CureVac to Report Third Quarter and First Nine Months 2024 Financial Results and Business Update on November 12, 2024

1 year ago

TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / November 7, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company…

TRNR Announces 1-for-100 Reverse Split

1 year ago

Split Becomes Effective Monday, November 11, 2024Shareholder- and Board-Approved Action Reduces Shares Outstanding to 313,235 from 31 Million, Ensures Continued…

Moderna Reports Third Quarter 2024 Financial Results and Provides Business Updates

1 year ago

Reports third quarter revenues of $1.9 billion, GAAP net income of $13 million and GAAP EPS of $0.03Achieves year-to-date product…

Promising cooperation between medac and chiron for the development of organ-on chip technology

1 year ago

WEDEL, Germany, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Testing new substances in animals is a regulatory cornerstone of drug development.…

Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-108 (HSV-1 oncolytic virus) to Treat Malignant Glioma

1 year ago

MB-108 (HSV-1 oncolytic virus) is active and well tolerated in patients with recurrent glioblastoma in ongoing Phase 1 clinical trial…

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2024

1 year ago

Conference Call Scheduled for Thursday, November 14, 2024 at 9:00 AM ETPORTLAND, Maine, Nov. 07, 2024 (GLOBE NEWSWIRE) -- ImmuCell…